Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Route-specific regimens:
- Central DI (DDAVP tablets, US): Start 0.05 mg twice daily. The label says most clinical-trial patients had an optimal total daily dose of 0.1–0.8 mg and permits individualized adjustment within 0.1–1.2 mg/day, divided into two or three doses.
- Central DI (intranasal): 5–40 mcg/day in 1–3 divided doses
- Central DI (injectable): 2–4 mcg SC/IV/IM
- PNE (oral): 0.2–0.4 mg at bedtime, fluid restriction
- Nocturia (sublingual Nocdurna): Women — 25 mcg at bedtime; Men — 50 mcg at bedtime (sex-specific dosing per FDA label)
- Haemophilia A/vWD (Stimate intranasal spray): 150 mcg (one spray) per nostril; 300 mcg total dose (two sprays)
- Haemophilia A/vWD (DDAVP injection): 0.3 mcg/kg IV in 50 mL NS over 15–30 min
- Stimate is a high-concentration intranasal spray; DDAVP injection is a separate product with a different formulation, route, and dose. These are NOT interchangeable.